Us Assisted Reproductive Technology Market Report: Market Size & Forecast 2026

The U.S. ART market is anchored by a nationwide network of fertility clinics that collectively perform hundreds of thousands of treatment cycles annually. The Centers for Disease Control and Prevention (CDC) maintains the National ART Surveillance System, mandated by Congress, which tracks clinical outcomes across operating fertility clinics to ensure standardized reporting and quality benchmarking.

• •The CDC's 2020 ART report documented data from 449 operational fertility clinics across the United States, providing verified clinical details and success metrics.
• •IVF cycle volume in the U.S. surged over 234% within a single decade, reflecting substantial growth in treatment demand and clinic capacity.

Several interrelated factors are propelling the North American ART market forward at an 8.2% compound annual growth rate. Rising prevalence of infertility, linked to lifestyle factors, advancing maternal age, and environmental conditions, has expanded the addressable patient population. Concurrently, broader insurance coverage mandates, growing social acceptance of fertility treatments, and declining stigma around assisted reproduction have reduced financial and cultural barriers to care.

• •Supportive government frameworks and policy initiatives across North America and Europe have been identified as key catalysts for continuous expansion of the reproductive health market.
• •Advancements in minimally invasive procedures, genetic screening technologies, and ovarian stimulation protocols have improved treatment accessibility and success rates, fueling patient demand.

The ART market spans multiple segments including fresh IVF cycles, frozen embryo transfers, egg and embryo cryopreservation, third-party reproduction, and fertility preservation services. North America commands a substantial share of the global market, with the United States serving as the primary engine of growth due to its concentration of specialized clinics, research institutions, and biotechnology infrastructure.

• •Europe and North America together account for approximately 65% of the global ART market footprint, reflecting higher per-capita utilization and more developed regulatory frameworks.
• •Within North America, the United States represents the largest market by revenue, supported by advanced clinical capabilities, extensive third-party reimbursement coverage in many states, and a thriving fertility tourism sector.

What are the recent trends and outlook?

The market is moving toward greater integration of digital health tools, telemedicine for patient monitoring and consultations, and artificial intelligence applications for embryo selection and cycle optimization. Despite a noted decline in per-cycle live birth efficiency as treatment volumes have expanded, continued investment in research, improved protocols, and broader access initiatives are expected to sustain the market's growth trajectory through the decade.

• •Adjacent digital health and telehealth sectors related to fertility care are experiencing rapid expansion, with financial projections tracking sustained growth through the early 2030s.
• •Government-mandated clinical reporting and increased transparency around clinic success rates are expected to shape consumer decision-making and drive consolidation toward higher-performing providers over the forecast period.